Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
CODEXIS, INC. incurred term loan of up to $40.0 million with Innovatus Life Sciences Lending Fund I, LP at the greater of (i) Primate Rate and (ii) 7.50%, plus (b) 3.25% maturing 5th anniversary of the initial funding date.
- Instrument
- term loan
- Principal
- up to $40.0 million
- Counterparty
- Innovatus Life Sciences Lending Fund I, LP
- Rate
- the greater of (i) Primate Rate and (ii) 7.50%, plus (b) 3.25%
- Maturity
- 5th anniversary of the initial funding date
- Event
- incurrence
Exact text from the filing
Lenders listed on Schedule 1.1 thereto, pursuant to which Innovatus, as a Lender, has agreed to make certain term loans to the Company in the aggregate principal amount of up to $40.0 million (the “Term Loans”). Funding of the first $30.0 million tranche was completed on February 13, 2024. The Company will be eligible to draw on a second tranche of $10.0 million upon
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.98
CODEXIS, INC. entered into Loan Agreement with Innovatus Life Sciences Lending Fund I, LP valued at up to $40.0 million (effective 2024-02-13).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Innovatus Life Sciences Lending Fund I, LP
- Value
- up to $40.0 million
- Effective
- 2024-02-13
Exact text from the filing
On February 13, 2024, Codexis, Inc. (the “Company”) entered into a loan and security agreement (the “Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (“Innovatus”) as collateral agent and the Lenders listed on Schedule 1.1 thereto, pursuant to which Innovatus, as a Lender, has agreed to make certain term loans to the Company in the aggregate principal amount of up to $40.0 million (the “Term Loans”).
View on SEC.gov